Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  2011-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00280-010-1488-5PMID 20972873
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck

  2009cited by this paper
• Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study

  2008cited by this paper
• Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single‐agent therapy with imatinib

  2007cited by this paper
• Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Weekly Paclitaxel in Patients with Solid Tumors

  2007cited by this paper
• Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.

  2007cited by this paper
• Farnesyltransferase inhibitors.

  2005cited by this paper
• The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling

  2005cited by this paper
• Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane‐refractory/resistant nonsmall cell lung carcinoma

  2005cited by this paper
• Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors.

  2005cited by this paper
• Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors.

  2005cited by this paper
• Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

  2004cited by this paper
• Farnesyltransferase inhibitors.

  2004cited by this paper
• Therapeutic targeting in the estrogen receptor hormonal pathway.

  2004cited by this paper
• A tagging-via-substrate technology for detection and proteomics of farnesylated proteins.

  2004cited by this paper
• Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.

  2003cited by this paper
• Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.

  2002cited by this paper
• Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

  2001cited by this paper
• Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.

  2001cited by this paper
• Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.

  2001cited by this paper
• Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.

  2001cited by this paper
• Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.

  2001cited by this paper
• Biological effects and mechanism of action of farnesyl transferase inhibitors.

  2000cited by this paper
• A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

  2000cited by this paper
• Comparison of potential markers of farnesyltransferase inhibition.

  2000cited by this paper
• Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules*

  2000cited by this paper
• Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.

  1999cited by this paper
• Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

  1998cited by this paper
• Non-Ras targets of farnesyltransferase inhibitors: focus on Rho

  1998cited by this paper
• Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts

  1998cited by this paper
• Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB*

  1997cited by this paper
• Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo *

  1997cited by this paper
• Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I*

  1997cited by this paper
• K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors*

  1997cited by this paper
• Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?

  1997cited by this paper
• Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro(*)

  1995cited by this paper
• Mutagenesis of Active Site Residues in Type I Dehydroquinase from Escherichia coli

  1995cited by this paper
• Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.

  1992cited by this paper
• A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins.

  1991cited by this paper
• A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane.

  1990cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper

• In Vitro synergy of Farnesyltransferase inhibitors in combination with colistin against ESKAPE bacteria

  2025influential citation
• Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective.

  2025cites this paper
• Hepatitis D virus: Improving virological knowledge to develop new treatments.

  2022cites this paper
• HBV and HDV: New Treatments on the Horizon

  2021cites this paper
• Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials

  2021cites this paper
• Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

  2020cites this paper
• Strategies for the treatment of HBV/HDV

  2018cites this paper
• Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection

  2017influential citation
• Anti‐mitotic agents: Are they emerging molecules for cancer treatment?☆

  2017cites this paper
• Prediction of Apparent Oral Clearance of Small-Molecule Inhibitors in Pediatric Patients.

  2017cites this paper
• Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

  2014cites this paper
• Disruption of lamin B1 and lamin B2 processing and localization by farnesyltransferase inhibitors

  2013cites this paper
• Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

  2013cites this paper
• Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.

  2013cites this paper
• Is there a future for prenyltransferase inhibitors in cancer therapy?

  2012cites this paper
• Synthesis and biological evaluation of cyanoguanidine derivatives of loratadine.

  2012cites this paper
• Lonafarnib for cancer and progeria

  2012cites this paper
• A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma

  2011cites this paper
• Farnesyltransferase Inhibitor in Cancer Treatment

  2011cites this paper
• A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer

  2011cites this paper